Allergy

Biosimilars

Cardiology

Dermatology

Endocrinology

Family Medicine

Gastroenterology

Geriatrics

Hospital Medicine

Infectious Disease

Internal Medicine

Nephrology

Neurology

Obesity Management

Ophthalmology

Pain

Pediatrics

Psychiatry

Pulmonology

Rare Disease Report®

Rheumatology

Sleep

Surgery

Women's Health

News

Media

Medical World News

Podcasts

Shows

State Of Sciences - Presentations

Videos

Webinars

Multimedia Series

Insights

Medcast Podcasts

Medcast Videos

Peer Exchange

Peers & Perspectives

Conferences

Conference Coverage

Conference Listing

Partners

CME/CE

Resources

Interactive Tools

Live Events

Press Release

Publications

Subscribe

Connor Iapoce is an associate editor for 

 and joined the MJH Life Sciences team in April 2021. He graduated from The College of New Jersey with a degree in Journalism and Professional Writing. He enjoys listening to records, going to concerts, and playing with his cat Squish. You can reach him at 

Articles

The second pivotal Phase 3 trial reported NOV03 consistently met primary endpoints for signs and symptoms of DED associated with meibomian gland dysfunction.

Phase 3 MOJAVE Trial Reports Efficacy of NOV03 for Dry Eye Disease 

Phase 2/3 data show significant improvement in lymphoproliferation as measured by the reduction in lymph node size and increase in naïve B cells in patients with activated phosphoinositide 3-kinase delta syndrome.

Leniolisib Becomes First FDA-Approved Treatment for Rare Immunodeficiency Disease

The results of a comprehensive meta-analysis indicate a high prevalence of comorbidities among asthma patients, emphasizing the importance of effective treatment strategies.

Beyond Asthma: Study Examines the Strength of Comorbidity Associations

Lana Pine is the editor of HCPLive Rheumatology. She is an experienced editor and technical writer with a demonstrated history of working in the banking and publishing industries. In her free time, she enjoys cooking, yoga, listening to podcasts, and drawing. She can be reached via email at LPine@mjhlifesciences.com.

Upadacitinib, a selective and reversible Janus kinase (JAK) inhibitor, may be a promising treatment option for patients with systemic lupus erythematosus. 

Phase 2 Trial Reaches Primary Endpoint for Upadacitinib Treatment in Active SLE

HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care to patients. At HCPLive, you will find breaking news, video interviews with physician experts, in-depth conference coverage, finance and practice management updates, insight and analysis from physician contributors, and more.

Shomari Hearn

Articles